Supervisory board member joins Bayer
pharmafile | October 9, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |ย ย Bayer, Otmar Wiestlerย
Professor Otmar Wiestler has been appointed to the supervisory board at German pharma giant Bayer.
He replaces Dr Klaus Kleinfeld who left the firm at his own request at the end of September in order to concentrate on his other offices and honorary posts, some of which are in the US.
Since 2004 Wiestler has been chairman of the management board and scientific director of the German Cancer Research Center (DKFZ) in Heidelberg.
He has also been chairman of the advisory committee and a member of the board of German Cancer Aid, and from 2007 to 2012 was a vice-president in the executive committee of the Helmholtz Association.
โWe would like to thank Mr Kleinfeld for our very successful and trusting co-operation. In professor Wiestler we have found a competent successor with extensive scientific expertise,” says Werner Wenning, Bayerโs chairman of the supervisory board.
Related Content

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Third application for Orionโs prostate cancer drug submitted by partner Bayer
Finnishย pharmaceutical company Orion has announced that its partner Bayer is applying for a third application …

Bayer and Evotec to collaborate on precision cardiology
Bayer and Evotec have announced that they have updated the focus of their collaboration to …






